Mark Kirschbaum
- Hematology top 0.2%
- Acute Myeloid Leukemia Research 23
- Hematopoietic Stem Cell Transplantation 9
- Chronic Myeloid Leukemia Treatments 6
- Transplantation top 1%
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 12
- Immunology top 1%
- Oncology top 1%
-
- Histone Deacetylase Inhibitors Research 29
- Protein Degradation and Inhibitors 10
-
- Lymphoma Diagnosis and Treatment 24
-
- Acute Lymphoblastic Leukemia research 8
- Co-authors
- Shimon SlavinArnon NaglerGàbor VaradiReuven OrAvraham AmarSimcha SamuelChaim BrautbarAliza Ackerstein
- Cited by
- HematologyTransplantationGenetics
- Partner nations
- United StatesAustraliaIsrael
In The Last Decade
Mark Kirschbaum
65 papers receiving 6.0k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Hematology 3.2k
- Transplantation 263
- Genetics 887
- Immunology 1.7k
- Oncology 2.1k
Countries citing papers authored by Mark Kirschbaum
This map shows the geographic impact of Mark Kirschbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kirschbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kirschbaum more than expected).
Fields of papers citing papers by Mark Kirschbaum
This network shows the impact of papers produced by Mark Kirschbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kirschbaum. The network helps show where Mark Kirschbaum may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Kirschbaum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 34 | |
| 2 | 2016 | 11 | |
| 3 | 2015 | 61 | |
| 4 | 2013 | 59 | |
| 5 | 2013 | 15 | |
| 6 | 2012 | 6 | |
| 7 | 2011 | 89 | |
| 8 | 2011 | 14 | |
| 9 | 2011 | 19 | |
| 10 | 2011 | 59 | |
| 11 | A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells. | 2008 | 15 |
| 12 | Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228 | 2008 | 1 |
| 13 | 2008 | 31 | |
| 14 | 2008 | 1 | |
| 15 | 2008 | 78 | |
| 16 | 2007 | 32 | |
| 17 | 2006 | 81 | |
| 18 | 1999 | 460 | |
| 19 | 1999 | 36 | |
| 20 | 1998 | 51 |
About Mark Kirschbaum
Mark Kirschbaum is a scholar working on Hematology, Pathology and Forensic Medicine and Genetics, having authored 66 papers that have together received 6.2k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (29 papers), Lymphoma Diagnosis and Treatment (24 papers), Acute Myeloid Leukemia Research (23 papers), Chronic Lymphocytic Leukemia Research (12 papers), Protein Degradation and Inhibitors (10 papers), Hematopoietic Stem Cell Transplantation (9 papers), Acute Lymphoblastic Leukemia research (8 papers) and Chronic Myeloid Leukemia Treatments (6 papers). The work is most often cited by research in Hematology (3.2k citations), Transplantation (263 citations) and Genetics (887 citations). Mark Kirschbaum has collaborated with scholars based in United States, Australia and Israel. Frequent co-authors include Shimon Slavin, Arnon Nagler, Gàbor Varadi, Reuven Or, Avraham Amar, Simcha Samuel, Chaim Brautbar, Aliza Ackerstein, E Naparstek and Memet Aker. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Journal of Cellular Biochemistry and Bone Marrow Transplantation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.